IV Vitamin C Selectively Kills Cancer Cells, Review Finds
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Linus Pauling teamed up with Scottish doctor Ewan Cameron in the 1970s, giving terminal cancer patients high-dose vitamin C — first intravenously, then as tablets — and reporting significantly longer survival in the treated group.
- Two large Mayo Clinic trials later found no benefit from vitamin C pills, discrediting Pauling for decades, but critics and defenders both missed that Pauling and Cameron had started with IV administration, not oral.
- Intravenous vitamin C bypasses the gut's absorption ceiling and reaches blood concentrations "tens or even hundreds of times higher" than pills, where it flips from antioxidant to pro-oxidant and generates hydrogen peroxide that selectively kills stressed cancer cells while sparing healthy ones — behaving "like a weak, selective chemotherapy drug."
- Small clinical trials in hard-to-treat cancers including ovarian, pancreatic, and brain tumors show high-dose IV vitamin C can be given multiple times weekly without serious side effects, though patients with poor kidney function or rare inherited conditions face elevated risk.
- The most consistent clinical signal across studies is quality-of-life improvement: patients receiving IV vitamin C alongside chemotherapy commonly report less fatigue, pain, and nausea, even when survival benefits remain unproven.
- Large, definitive randomized trials are still lacking; the review frames high-dose IV vitamin C as experimental and appropriate only for clinical trials or supervised medical settings, explicitly warning against commercial "immune boost" clinics.
Why it matters: For cancer patients, IV vitamin C remains experimental — no large definitive trial has yet shown it prolongs survival, and commercial 'immune boost' drips lack the evidence to justify their cost. The research shift legitimizes studying it as a selective adjunct to chemotherapy, but the practical takeaway is to wait for trial results, not high-street infusions.
